WorldSTORY FILE
Women with PMOS should get subsidised weight-loss drugs, Australian advocates say
<p>With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label</p><ul><li><p>Get our <a href="https://www.theguardian.com/email-newsletters?CMP=cvau_sfl">breaking news email</a>, <a href="https://app.adjust.com/w4u7jx3">free app</a> or <a href="https://www.theguardian.com/australia-news/series/full-story?CMP=cvau_sfl">daily news podcast</a></p></li></ul><p>Women living with a chronic hormonal condition should have access to taxpayer-funded weight-loss medications, advocates say.</p><p>The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.</p> <a href="https://www.theguardian.com/australia-news/2026/oct/10/women-with-pmos-should-get-subsidised-weight-loss-drugs-advocates-say">Continue reading...</a>
There’s more to the story.
You’re reading material shared in The Guardian Australia’s RSS feed. Continue with the original publisher for the complete story.
Continue at The Guardian AustraliaOriginal reporting remains with its publisher.Back to the edition